Skip to main content

Table 3 Incidence of uveitis with mAb and ETA, without and with adjustment for propensity score (PS)

From: Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: comparing the soluble receptor to monoclonal antibodies in a large observational cohort

  ETA versus mAb (reference = mAb)
Qualitative analysisQuantitative analysis
OR [95% CI]pRR [95% CI]p
First year of TNF inhibitor treatmentUnadjusted for PS0.81 [0.32, 2.03]0.650.54 [0.24, 1.24]0.15
Adjusted for PS0.94 [0.35, 2.54]0.900.62 [0.26, 1.46]0.27
First-line TNF inhibitorUnadjusted for PS*1.39 [0.71, 2.72]0.300.97 [0.66, 1.43]0.89
Adjusted for PS*1.89 [0.90, 4.01]0.091.10 [0.70, 1.72]0.68
All therapeutic lines of TNF inhibitorsUnadjusted for PS*1.57 [0.71, 3.46]0.271.01 [0.61; 1.69]0.96
Adjusted for PS*1.98 [0.90, 4.37]0.081.21 [0.68, 2.16]0.53
  1. OR odds ratio, RR relative risk, 95% CI 95% confidence interval
  2. *Adjusted for duration of TNF inhibitor treatment